Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
ConclusionsCauses for the observed mortality imbalance associated with revusiran were thoroughly investigated and no clear causative mechanism could be identified. Although the results suggest similar progression of cardiac parameters in both treatment arms, a role for revusiran cannot be excluded.Clinical Trial RegistrationNCT02319005.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Amyloidosis | Cardiology | Cardiomyopathy | Cardiovascular | Clinical Trials | Heart | Heart Failure | Study